Scailyte, a Luzern based startup specializing in single-cell technologies for precision medicine and early detection of complex diseases, has raised CHF 2.75M in seed funding.
Scailyte, a Luzern based startup specializing in single-cell technologies for precision medicine and early detection of complex diseases, has raised CHF 2.75M in seed funding. The fund will flow into product development and accelerating market entry.
Scailyte develops artificial intelligence (AI) based software for best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery and precision diagnostics. The software for biomedical research, commercialized under the brand ScaiVision, will be launched at the beginning of 2019. Scailyte also offers biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.
Following the closing of its financing round, Scailyte has won Swisscom Ventures as a strategic investor following the. Zürcher Kantonalbank ( ZKB ) also joined the round, alongside the existing shareholders, thus reaffirming their trust in the competence and vision of Scailyte’s team. The raised capital will be used to enhance the market entry and to speed up further development of ScaiVision, allowing it to be more accessible and attractive to a wider range of customers.
“The future of healthcare is about detecting and understanding valuable information hidden in complex data patterns,” says Peter Nestorov, CEO of Scailyte. “With our AI-based software for single-cell data interpretation, we will accelerate biomedical discovery and enable the next generation of precision diagnostics. With the support of strong partners like Swisscom Ventures and Zürcher Kantonalbank, we will grow to become pioneers and leaders in the fast emerging Single-Cell Analysis market, enabling the clinical application of single-cell data.”
According to Swisscom Ventures, single-cell analysis technology will bring precision medicine to the next level. The firm was impressed by Scailyte’s team, who bring together unique skills from both computational biology and Next-Generation Sequencing device markets.
Scailyte welcomes new members on Board
Dominique Megret, Head of Swisscom Ventures, will join the Board of Directors of Scailyte, along with Pascal Winnen, CEO of Hemex AG.
“Hemex has supported the development of several innovative therapies and immediately recognized the potential of Scailyte’s technology to unlock «big data» in order to find more precise, personalized cures and even detect diseases before they manifest clinically in patients. We are proud to join Scailyte at the forefront of AI single-cell data analysis”, said Winnen.[…]